|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/675 | (2006.01) |
| A61K 31/7076 | (2006.01) | ||
| C07H 23/00 | (2006.01) | ||
| C07H 19/16 | (2006.01) | ||
| C07H 19/207 | (2006.01) | ||
| C07H 19/20 | (2006.01) | ||
| A61P 1/00 | (2006.01) | ||
| A61P 31/14 | (2006.01) |
| (11) | Number of the document | 3512863 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17849474.6 |
| Date of filing the European patent application | 2017-09-06 | |
| (97) | Date of publication of the European application | 2019-07-24 |
| (45) | Date of publication and mention of the grant of the patent | 2021-12-08 |
| (46) | Date of publication of the claims translation | 2022-03-10 |
| (86) | Number | PCT/US2017/050323 |
| Date | 2017-09-06 |
| (87) | Number | WO 2018/048937 |
| Date | 2018-03-15 |
| (30) | Number | Date | Country code |
| 201662384664 P | 2016-09-07 | US |
| (72) |
SOMMADOSSI, Jean-Pierre , US
MOUSSA, Adel , US
|
| (73) |
ATEA Pharmaceuticals, Inc. ,
125 Summer Street, Boston, MA 02110,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | 2'-Pakeistieji-N6-pakeistieji purino nukleotidai, skirti gydymui RNR virusu |
| 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT |
| Payment date | Validity (years) | Amount | |
| 2025-07-24 | 9 | 208.00 EUR |
| 2026-09-06 |